Investigation of Half-Life and Clinical Effects of Ceftizoxime in Premature and Newborn Infants
Dr Ryochi Fujii
Clinical Drug Investigation 2(3): 143-149
1990
ISSN/ISBN: 1173-2563 DOI: 10.1007/bf03259187
Accession: 062109869
The pharmacokinetics and clinical efficacy of ceftizoxime in premature infants and neonates were investigated. The serum half-life (t1/2) of ceftizoxime (20 mg/kg, bolus intravenous administration) at ages 0 to 3, 4 to 7, 8 to 14 and 15 to 30 days was 4.1, 3.0, 2.6 and 2.0 hours for neonates and 5.3, 4.6, 3.7 and 2.6 hours for premature infants, respectively. The excretion rate (percentage of administered dose) of ceftizoxime in urine over the first 6 hours after intravenous bolus injection of 20 mg/kg in neonates aged 0 to 3 days, was about 35% and 45 to 55% in those 4 days old and over. Percentage excretion was about 30% in premature infants aged 0 to 3 days and about 45% in those aged 4 days and over.